1h Free Analyst Time
In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market ReportSpeak directly to the analyst to clarify any post sales queries you may have.
Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients. Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.
The global biomarkers market is expected to grow at a CAGR of 11.44%.
KEY HIGHLIGHTS
- Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them.
- Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinson’s and Alzheimer's disease and clinical outcome assessments.
- Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers.
- Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.
GROWTH ENABLERS
- Increase In Number of Pipeline Biomarkers
- Rising Adoption of Biomarkers In Disease Diagnostics
- Technological Advancements in Biomarker Discovery
GLOBAL BIOMARKERS MARKET SEGMENTATION
Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.
Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost
Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.
Segmentation by Indication
- Oncology
- Cardiology
- Neurology
- Immunology
- Others
Segmentation by Application
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine (PM)
- Others
Segmentation by Type
- Diagnostic Biomarker
- Monitoring Biomarker
- Prognostic Biomarker
- Susceptibility Biomarker
- Other Biomarker
VENDOR ANALYSIS
Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.
Key Vendors
- Abbott company
- BioMerieux
- Biohit OYJ
- CENTOGENE
- Creative Diagnostics
- F. Hoffmann-La Roche company
- Fujirebio
- General Electric (GE) company
- TAmiRNA
Other Prominent Vendors
- Accure Therapeutics
- Agilent
- Almac Group
- Applied Research Using OMIC Sciences (AROMICS)
- Bio-Rad Laboratories
- BioVision
- Caris Life Sciences
- Denovo Biopharma
- Dreamgenics
- Eisai
- Epigenomics
- Immunovia
- Insilico Medicine
- Lexogen
- Monument Tx
- Oryzon Genomics
- Plexision
- Rules-Based Medicine
- Siemens Healthineers
- Second Genome Therapeutics
- Thermo Fisher Scientific
- Ymir Genomics
GEOGRAPHICAL ANALYSIS
North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.
APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.
Segmentation by Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
THE REPORT INCLUDES:
1. The analysis of the global Biomarkers market size and growth rate for the forecast period 2022-2027.
2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global Biomarkers market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook of the Biomarkers market.
Table of Contents
1 Research Methodology2 Research Objectives3 Research Process6 Market at a Glance
4 Scope & Coverage
5 Report Assumptions & Caveats
7 Introduction
8 Market Opportunities & Trends
9 Market Growth Enablers
10 Market Restraints
11 Market Landscape
12 Indication
13 Application
14 Type
15 Geography
16 North America
17 Europe
18 Apac
19 Latin America
20 Middle East & Africa
21 Competitive Landscape
22 Key Company Profiles
23 Other Prominent Vendors
24 Report Summary
25 Quantitative Summary
26 Appendix
Companies Mentioned
- Abbott company
- BioMerieux
- Biohit OYJ
- CENTOGENE
- Creative Diagnostics
- F. Hoffmann-La Roche company
- Fujirebio
- General Electric (GE) company
- TAmiRNA
- Accure Therapeutics
- Agilent
- Almac Group
- Applied Research Using OMIC Sciences (AROMICS)
- Bio-Rad Laboratories
- BioVision
- Caris Life Sciences
- Denovo Biopharma
- Dreamgenics
- Eisai
- Epigenomics
- Immunovia
- Insilico Medicine
- Lexogen
- Monument Tx
- Oryzon Genomics
- Plexision
- Rules-Based Medicine
- Siemens Healthineers
- Second Genome Therapeutics
- Thermo Fisher Scientific
- Ymir Genomics
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
